IMMUSOFT CORP has a total of 28 patent applications. Its first patent ever was published in 2011. It filed its patents most often in Canada, EPO (European Patent Office) and United States. Its main competitors in its focus markets biotechnology, pharmaceuticals and foods and drinks are CENTRO DE INVESTIG ENERGETICAS MEDIOAMBIENTALES Y TECNOLOGICAS O A M P, BEAM THERAPEUTICS INC and AN YIHUA.
# | Country | Total Patents | |
---|---|---|---|
#1 | Canada | 5 | |
#2 | EPO (European Patent Office) | 5 | |
#3 | United States | 5 | |
#4 | WIPO (World Intellectual Property Organization) | 5 | |
#5 | Australia | 2 | |
#6 | China | 2 | |
#7 | Japan | 2 | |
#8 | Brazil | 1 | |
#9 | Hong Kong | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Foods and drinks | |
#4 | Agriculture |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Medical preparations | |
#3 | Peptides | |
#4 | Therapeutic chemical compounds | |
#5 | Enzymes | |
#6 | Animal care |
# | Name | Total Patents |
---|---|---|
#1 | Scholz Matthew Rein | 23 |
#2 | Herbig Eric J | 23 |
#3 | Mcivor R Scott | 11 |
#4 | Xu Mei | 10 |
#5 | De Laat Rian | 9 |
#6 | Olson Erik | 5 |
#7 | Matthew Rein Scholz | 3 |
#8 | Eric J Herbig | 3 |
#9 | Mei Xu | 2 |
#10 | Scholz Matthew | 1 |
Publication | Filing date | Title |
---|---|---|
CA3093716A1 | B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength | |
AU2018256887A1 | B cells for in vivo delivery of therapeutic agents and dosages thereof | |
US2018185487A1 | Method to achieve extended expression of dna infused into liver | |
EP3234107A1 | B cells for in vivo delivery of therapeutic agents | |
EP2971039A1 | Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors | |
WO2011085247A2 | Vectors and methods for transducing b cells |